Clover Health Investments Future Growth
Future criteria checks 0/6
Clover Health Investments's revenue is forecast to decline at 5.9% per annum while its annual earnings are expected to grow at 26.1% per year. EPS is expected to grow by 26.2% per annum. Return on equity is forecast to be -23.6% in 3 years.
Key information
26.1%
Earnings growth rate
26.2%
EPS growth rate
Healthcare earnings growth | 21.0% |
Revenue growth rate | -5.9% |
Future return on equity | -23.6% |
Analyst coverage | Low |
Last updated | 09 May 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,413 | -81 | N/A | N/A | 2 |
12/31/2025 | 1,349 | -95 | N/A | N/A | 3 |
12/31/2024 | 1,338 | -107 | N/A | N/A | 2 |
3/31/2024 | 2,059 | -157 | N/A | N/A | N/A |
12/31/2023 | 2,036 | -213 | -116 | -116 | N/A |
9/30/2023 | 2,440 | -226 | -101 | -96 | N/A |
6/30/2023 | 2,841 | -260 | 20 | 24 | N/A |
3/31/2023 | 3,195 | -336 | -72 | -68 | N/A |
12/31/2022 | 3,579 | -340 | -291 | -286 | N/A |
9/30/2022 | 3,041 | -443 | -76 | -75 | N/A |
6/30/2022 | 2,564 | -402 | -222 | -222 | N/A |
3/31/2022 | 2,075 | -615 | -247 | -246 | N/A |
12/31/2021 | 1,361 | -588 | -283 | -282 | N/A |
9/30/2021 | 1,158 | -527 | -263 | -262 | N/A |
6/30/2021 | 922 | -487 | -252 | -252 | N/A |
3/31/2021 | 721 | -160 | -175 | -174 | N/A |
12/31/2020 | 690 | -136 | -119 | -118 | N/A |
9/30/2020 | 624 | -89 | -126 | -126 | N/A |
6/30/2020 | 572 | -145 | -116 | -116 | N/A |
3/31/2020 | 507 | -272 | -163 | -163 | N/A |
12/31/2019 | 455 | -364 | -160 | -160 | N/A |
12/31/2018 | 281 | -202 | -155 | -153 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 7QD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 7QD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 7QD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 7QD's revenue is expected to decline over the next 3 years (-5.9% per year).
High Growth Revenue: 7QD's revenue is forecast to decline over the next 3 years (-5.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 7QD is forecast to be unprofitable in 3 years.